DNA’s chemical cousin, RNA, was the messenger that carries DNA instructions from the double helix in the cell’s nucleus to ...

Over the last few years, scientists and entrepreneurs have flocked to developing medicines that target RNA, the genetic ...

Yale researchers have developed a new and safe family of RNA-editing tools that utilize an RNA-targeting activity that they ...

The global Live Cell RNA Detection Market is set for robust expansion, with valuation projected to rise from USD 3.4 billion ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

This review, led by Prof. Bochen Jiang at the School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, provides a comprehensive ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Now that scientists understand the role of RNA glycosylation in deflecting immune system attention, they can check on whether that strategy is somehow going awry.